| Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share |
The
Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed
Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:
Schedule
of Comparison of Basic and Fully Diluted Net Loss Per Share
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| | |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| | |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| Numerator | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) - before noncontrolling interest | |
$ | 60,711 | | |
$ | (21,750 | ) | |
$ | 27,285 | | |
$ | (61,855 | ) |
| Net income (loss) attributable to noncontrolling interest | |
| 3,688 | | |
| 4,079 | | |
| 11,075 | | |
| 11,716 | |
| Net income (loss) - as reported, attributable to PAVmed Inc. | |
$ | 64,399 | | |
$ | (17,671 | ) | |
$ | 38,360 | | |
$ | (50,139 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Series B Convertible Preferred Stock dividends – earned | |
$ | (83 | ) | |
$ | (77 | ) | |
$ | (244 | ) | |
$ | (226 | ) |
| Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests | |
$ | — | | |
$ | — | | |
$ | (7,496 | ) | |
$ | — | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation | |
$ | 64,316 | | |
$ | (17,748 | ) | |
$ | 30,620 | | |
$ | (50,365 | ) |
| Fair Value Adjustment for diluted EPS calculation | |
$ | (240 | ) | |
$ | — | | |
$ | 3,378 | | |
$ | — | |
| Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation | |
$ | 64,076 | | |
$ | (17,748 | ) | |
$ | 33,998 | | |
$ | (50,365 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| Denominator | |
| | | |
| | | |
| | | |
| | |
| Weighted average common shares outstanding, basic | |
| 10,005,379 | | |
| 7,462,751 | | |
| 9,286,999 | | |
| 6,967,764 | |
| Weighted average common shares outstanding, diluted | |
| 44,475,638 | | |
| 7,462,751 | | |
| 43,069,449 | | |
| 6,967,764 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) per
share (1) | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) per share attributable to PAVmed Inc. common
stockholders, basic (1) | |
$ | 6.43 | | |
$ | (2.38 | ) | |
$ | 3.30 | | |
$ | (7.23 | ) |
| Net income (loss) per share attributable to PAVmed Inc. common
stockholders, diluted (1) | |
$ | 1.44 | | |
$ | (2.38 | ) | |
$ | 0.79 | | |
$ | (7.23 | ) |
| (1) | - Convertible preferred
stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating
net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses,
there is no impact on the Company’s net income (loss) per share calculation for the periods indicated. |
|
| Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share |
Schedule
of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share
| | |
2024 | | |
2023 | |
| | |
September 30, | |
| | |
2024 | | |
2023 | |
| Stock options | |
| 1,233,107 | | |
| 1,138,632 | |
| Restricted stock awards | |
| — | | |
| 70,528 | |
| Series Z Warrants | |
| 795,830 | | |
| 795,830 | |
| Series B Convertible Preferred Stock | |
| — | | |
| 85,307 | |
| Total | |
| 2,028,937 | | |
| 2,090,297 | |
|